1. Home
  2. AZTR vs APM Comparison

AZTR vs APM Comparison

Compare AZTR & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTR
  • APM
  • Stock Information
  • Founded
  • AZTR 2014
  • APM 2010
  • Country
  • AZTR United States
  • APM United Kingdom
  • Employees
  • AZTR N/A
  • APM N/A
  • Industry
  • AZTR Biotechnology: Pharmaceutical Preparations
  • APM Biotechnology: Pharmaceutical Preparations
  • Sector
  • AZTR Health Care
  • APM Health Care
  • Exchange
  • AZTR Nasdaq
  • APM Nasdaq
  • Market Cap
  • AZTR 3.7M
  • APM 6.9M
  • IPO Year
  • AZTR 2023
  • APM 2018
  • Fundamental
  • Price
  • AZTR $0.94
  • APM $2.64
  • Analyst Decision
  • AZTR
  • APM
  • Analyst Count
  • AZTR 0
  • APM 0
  • Target Price
  • AZTR N/A
  • APM N/A
  • AVG Volume (30 Days)
  • AZTR 1.5M
  • APM 20.0M
  • Earning Date
  • AZTR 08-11-2025
  • APM 04-30-2025
  • Dividend Yield
  • AZTR N/A
  • APM N/A
  • EPS Growth
  • AZTR N/A
  • APM N/A
  • EPS
  • AZTR N/A
  • APM N/A
  • Revenue
  • AZTR N/A
  • APM N/A
  • Revenue This Year
  • AZTR N/A
  • APM N/A
  • Revenue Next Year
  • AZTR N/A
  • APM N/A
  • P/E Ratio
  • AZTR N/A
  • APM N/A
  • Revenue Growth
  • AZTR N/A
  • APM N/A
  • 52 Week Low
  • AZTR $0.81
  • APM $0.46
  • 52 Week High
  • AZTR $5.06
  • APM $7.49
  • Technical
  • Relative Strength Index (RSI)
  • AZTR 31.60
  • APM 59.96
  • Support Level
  • AZTR $0.81
  • APM $1.26
  • Resistance Level
  • AZTR $1.07
  • APM $4.47
  • Average True Range (ATR)
  • AZTR 0.11
  • APM 0.26
  • MACD
  • AZTR 0.00
  • APM 0.17
  • Stochastic Oscillator
  • AZTR 22.02
  • APM 43.87

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Share on Social Networks: